Having recently trimmed back its pipeline to a sole cancer candidate, Pyxis Oncology has now reduced its head count to match. | Having recently trimmed back its pipeline to a sole cancer candidate, ...
Greece’s Pyxis Tankers plans to take advantage of falling vessel values to grow the fleet in the near future. The ...
Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including ...
Hosted on MSN19d
FDA grants fast track status to Pyxis’ PYX-201This trial is part of a clinical trial partnership agreement with biopharmaceutical company MSD. Pyxis oncology president and CEO Lara Sullivan stated: “Receiving fast track designation for PYX-201 ...
Pyxis’ President and CEO, Dr. Lara S. Sullivan, emphasized the significance of this designation in meeting the urgent medical needs for affected patients and accelerating the drug's development ...
Q4 Sales $12.035M, consensus $10.5M…For the three months ended December 31, revenues, net were $12M. For the same period, ...
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology ... Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback